TSPAN32 and myeloid sarcoma: This is in accordance with data from the GSE19224 dataset, that show an adjusted p value > 0.99 and a log2(fold) change of 0.276 for TSPAN32 expression levels when comparing PBMCs from MS patients in stable versus relapsing disease (https://www.ncbi.nlm.nih.gov/geo/geo2r/?acc=GSE19224).